Improving lung cancer treatment with noninvasive imaging and blood tests
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11090525
This study is looking to improve lung cancer treatment by finding better ways to see how well immunotherapy works for patients, helping doctors know early on who will benefit most from the treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11090525 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy for lung cancer patients by developing noninvasive imaging techniques and blood-based biomarkers. The goal is to identify which patients are likely to benefit from immune checkpoint inhibitors (ICIs) early in their treatment process. By utilizing advanced imaging and deep learning models, the study aims to provide more accurate predictions of treatment responses, addressing the limitations of current tissue-based biomarkers. This approach could lead to more personalized and effective treatment plans for patients with non-small cell lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer who are considering immunotherapy options.
Not a fit: Patients with early-stage lung cancer or those who do not qualify for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for lung cancer patients by enabling personalized immunotherapy strategies.
How similar studies have performed: Previous research has shown promise in using imaging and biomarkers for predicting treatment responses in cancer, suggesting that this approach could be effective.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, RUIJIANG — STANFORD UNIVERSITY
- Study coordinator: LI, RUIJIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy